Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
Molecular Cancer volume 10, Article number: 143 (2011)
Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) especially effective in tumors with activating EGFR gene mutations while EGFR wild-type non small cell lung cancer (NSCLC) patients at present do not benefit from this treatment.
The primary site of gefitinib metabolism is the liver, nevertheless tumor cell metabolism can significantly affect treatment effectiveness.
In this study, we investigated the intracellular metabolism of gefitinib in a panel of EGFR wild-type gefitinib-sensitive and -resistant NSCLC cell lines, assessing the role of cytochrome P450 1A1 (CYP1A1) inhibition on gefitinib efficacy. Our results indicate that there is a significant difference in drug metabolism between gefitinib-sensitive and -resistant cell lines. Unexpectedly, only sensitive cells metabolized gefitinib, producing metabolites which were detected both inside and outside the cells. As a consequence of gefitinib metabolism, the intracellular level of gefitinib was markedly reduced after 12-24 h of treatment. Consistent with this observation, RT-PCR analysis and EROD assay showed that mRNA and activity of CYP1A1 were present at significant levels and were induced by gefitinib only in sensitive cells. Gefitinib metabolism was elevated in crowded cells, stimulated by exposure to cigarette smoke extract and prevented by hypoxic condition. It is worth noting that the metabolism of gefitinib in the sensitive cells is a consequence and not the cause of drug responsiveness, indeed treatment with a CYP1A1 inhibitor increased the efficacy of the drug because it prevented the fall in intracellular gefitinib level and significantly enhanced the inhibition of EGFR autophosphorylation, MAPK and PI3K/AKT/mTOR signalling pathways and cell proliferation.
Our findings suggest that gefitinib metabolism in lung cancer cells, elicited by CYP1A1 activity, might represent an early assessment of gefitinib responsiveness in NSCLC cells lacking activating mutations. On the other hand, in metabolizing cells, the inhibition of CYP1A1 might lead to increased local exposure to the active drug and thus increase gefitinib potency.
Gefitinib is an orally active, selective EGFR TKI used in the treatment of patients with advanced-NSCLC carrying activating EGFR mutations . In fact, it is well established that gefitinib is more active in some patient subgroups, such as Asians, females, never smokers and adenocarcinoma histotypes which have a higher probability of harbouring activating mutations in the tyrosine kinase domain, the most frequent being L858R in exon 21 and Del (746-750) in exon 19 . As a consequence most of the NSCLCs containing wild-type EGFR receptor are excluded and hence the role of gefitinib for the treatment of NSCLC is limited. However, some studies have shown that patients without mutations responded to gefitinib with response rates reaching 6.6% [2, 3]. In addition to cancer cell genomic determinants of sensitivity, some pharmacokinetic parameters may also play a role in the variable response to gefitinib and other TKIs .
When administered at 250 mg/day, gefitinib is 60% orally absorbed and 90% plasma protein-bound [5, 6]. The very high distribution volume of gefitinib (1400 litres) clearly indicates that the drug is extensively distributed in tissues such as liver, kidney, gastrointestinal tract, lung and in tumors . A tendency to accumulate in the lung was observed with concentrations 10 times higher than in plasma . We have recently demonstrated in NSCLC cell lines that the uptake of gefitinib is an essentially active process leading to intracellular gefitinib concentrations more than two hundred times higher than outside the cells .
There are few data on gefitinib intracellular metabolism in tumors, the majority of the available data concerns liver metabolism. In vitro and in vivo studies indicate that in the liver gefitinib is mainly metabolized by cytochrome P450-dependent (CYP) activities, including CYP3A4, CYP3A5 and CYP2D6 [10–12]. The main metabolic pathway characterized by using human liver microsomes include morpholine ring opening, O-demethylation of the methoxy-substituent on the quinazoline ring structure and oxidative defluorination of the halogenated phenyl group [13, 14].
A study investigating the contribution of individual CYPs to gefitinib metabolism demonstrated that gefitinib disappeared with similar clearance when incubated with CYP3A4 or CYP2D6 enzymes, less efficiently with CYP3A5 or CYP1A1, whereas CYP1A2 and CYP1B1 were not involved in the metabolism of the drug . Incubation with CYP3A4 and to a lesser extent CYP3A5, produced a similar range of metabolites as that produced by liver microsomes , but the main plasma metabolite, the O-desmethyl derivative present at plasma concentrations similar to gefitinib , was formed predominantly through the CYP2D6 enzyme.
CYP1A1 is one of the three members of the CYP1 family mainly expressed in extra-hepatic tissue, involved in the metabolism of a large number of xenobiotics as well as a small number of endogenous substrates . Being expressed at a significant level in human lung , it might play a role in the metabolism of gefitinib by lung tumor cells and its activity might be involved in the variability of the drug response.
In experiments using lung microsomes, CYP1A1 was shown to produce significant amounts of the para-hydroxyaniline metabolite derived from oxidative defluorination of gefitinib. Hydroxyaniline metabolites produced by CYP1A1 can be oxidized to reactive quinone-imine derivatives that form adducts with nucleophilic groups of macromolecules or GSH and may be related to clinically relevant hepatotoxicity or interstitial lung disease .
Both mRNA and protein CYP1A1 levels in human lung are greatly induced by tobacco smoke  and it has been reported that lung microsomes from smokers may generate 12 times more gefitinib-derived reactive metabolites as compared to non-smokers .
The present study was designed to investigate gefitinib metabolism in a panel of EGFR wild-type NSCLC cell lines either sensitive or resistant to gefitinib. Our objective was to define a possible potential role of gefitinib metabolism in early evaluation of tumor response to gefitinib, to analyze conditions or factors that can alter tumor gefitinib metabolism and to test the effect of CYP1A1 inhibition on gefitinib efficacy.
The human NSCLC cell lines H322, Calu-3, H292, H460, H1299, A549, Calu-1 and SKLU-1 were cultured as recommended. Cell lines obtained from American Type Culture Collection (Manassas, VA, USA) were immediately expanded and frozen. Every four months all the cell lines were restarted from a frozen vial of the same batch of cells and no additional authentication was done in our laboratory. All cells were maintained under standard cell culture conditions at 37°C in a water-saturated atmosphere of 5% CO2 in air. As previously reported  cells showing in proliferation assays IC50 for gefitinib < 1 μM were considered sensitive (H322, H292, Calu-3) and cell lines with IC50 > 8 μM (H460, H1299, A549, Calu-1 and SKLU-1) were considered resistant.
Hypoxic conditions (0.5%O2) were established by placing the cells in a tissue culture incubator (Binder GmbH, Tuttlingen, Germany) with controlled O2 levels.
Preparation of cigarette smoke extract (CSE)
CSE preparation was made according to Carp and Janoff , with slight modifications. Briefly, one cigarette without filter was combusted using a modified syringe-driven apparatus and the smoke was bubbled through 50 ml of serum-free cell culture medium. This solution, considered to be 100% CSE, was filtered diluted with medium and applied to cell cultures within 30 min of preparation.
Genomic DNA was isolated using a PureGene DNA purification system (GENTRA SYSTEMS, Minneapolis, MN) and both the rs 4646903 (3798 T > C, variant allele CYP1A1*2A) and the rs 1048943 (2454 A > G, variant allele CYP1A1*2C) polymorphisms of the CYP1A1 gene that were characterized according to previously published methods, with minimal changes [20, 21]. All the tested cell lines carried a wild type homozygous genotype for both the polymorphisms.
Gefitinib (ZD1839/Iressa) and metabolites [morpholine ring-opening (M537194, M1), oxidative defluorinated (M387783, M2) and O-desmethyl (M523595, M3) derivatives] were kindly provided by AstraZeneca. α-naphthoflavone (α-NAP) was from Sigma Aldrich (St. Louis, MO, USA).
Cetuximab, erlotinib and lapatinib were from inpatient pharmacy. RAD001 and NVP-BEZ235 were provided by Novartis Institutes for BioMedical Research (Basel, Switzerland). Wortmannin, PD98059 and U0126 were from Sigma-Aldrich (St. Louis, MO).
[3H]gefitinib uptake by cells was determined as described recently .
Liquid chromatography tandem mass spectrometry (LC-MS/MS)
For LC-MS/MS analysis, the medium samples were treated with ethyl acetate, dried under nitrogen and refilled with methanol and aqueous formic acid (0.1 M), while the ethanolic extracts were diluted with aqueous formic acid (0.1 M).
LC analyses were carried out with an Agilent HP 1100 pump coupled with a API4000 triple-quadrupole mass spectrometer (Sciex, Concord, Canada) equipped with a TurboIonSprayTM interface and configured in Selected Reaction Monitoring (SRM) mode. Chromatography was performed on a Synergi Hydro-RP column (5 × 2.0 mm i.d., 2 μm; Phenomenex) using variable proportions of 10 mM aqueous formic acid and methanol/acetonitrile (95/5, v/v) mixture as the mobile phase.
The analytes were ionized in positive ion mode and the following SRM transitions were monitored: m/z 447 ([M+H]+) → 128 for Gefitinib; m/z 421 ([M+H]+) → 320 for Metabolite 1; m/z 445 ([M+H]+) → 128 for Metabolite 2; m/z 433 ([M+H]+) → 128 for Metabolite 3 and m/z 394 ([M+H]+) → 336 for Internal Standard. Erlotinib was used as Internal Standard.
Determination of cell growth
Cell number and viability were evaluated by cell counting, crystal violet staining and MTT colorimetric assay as previously described .
Western blot analysis
Procedures for protein extraction, solubilization, and protein analysis by 1-D PAGE are described elsewhere . Anti-EGFR, anti-phospho-EGFR (tyr1068), anti-phospho-p44/42 MAPK, anti-p44/42 MAPK, anti-phospho-AKT (Ser473), anti-AKT and anti-actin were from Cell Signaling Technology (Beverly, MA, USA).
Total RNA was isolated by the TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed as previously described . The transcript levels of CYP1A1, CYP1A2, CYP2D6, CYP3A4 and CYP3A5 genes were assessed by Real-Time qRT-PCR on an iCycler iQ Multicolor RealTime PCR Detection System (Bio-Rad, Hercules, CA, USA). Primers and probes included: CYP1A1-F (5'-TCCAAGAGTCCACCCTTCC-3'), CYP1A1-R (5'-AAGCATGATCAGTGTAGGGATCT-3'), CYP1A1-probe (5'-FAM CAGCCACC 3'DQ); CYP1A2-F (5'-GGCTTCTACATCCCCAAGAA-3'), CYP1A2-R (5'-CAGCTCTGGGTCATGGTTG-3'), CYP1A2-probe (5'-FAM CAGTGGCA 3'DQ); CYP2D6-F (5'-CTTCCAAAAGGCTTTCCTGA-3'), CYP2D6-R (5'-CAGGTCATCCTGTGCTCAGTT-3'), CYP2D6-probe (5'-FAM GCTGGATG 3'DQ); CYP3A4-F (5'-GATGGCTCTCATCCCAGACTT-3'), CYP3A4-R (5'AGTCCATGTGAATGGGTTCC-3'), CYP3A4-probe (5'-FAM TCCTCCTG 3'DQ); CYP3A5-F (5'-TGCCCAGTATGGAGATGTATTG-3'), CYP3A5-R (5'-GCTGTAGGCCCCAAAGATG-3'), CYP3A5-probe (5'-FAM GGAAGCAG 3'DQ); PGK1-F (5'-GGAGAACCTCCGCTTTCAT-3'), PGK1-R (5'-CTGGCTCGGCTTTAACCTT-3'), PGK1-probe (5'-FAM GGAGGAAG 3'DQ); RPL13-F (5'-ACAGCTGCTCAGCTTCACCT-3'), RPL13-R (5'-TGGCAGCATGCCATAAATAG-3'), RPL13-probe (5'-FAMCAGTGGCA3'DQ); HPRT-F (5'-TGACCTTGATTTATTTTGCATACC-3'), HPRT-R (5'CGAGCAAGACGTTCAGTCCT-3'), HPRT-probe (5'-FAM GCTGAGGA 3'DQ).
The amplification protocol consisted of 15 min at 95°C followed by 40 cycles at 94°C for 20 s and at 60°C for 1 min.
The relative transcript quantification was calculated using the geNorm algorithm for Microsoft Excel™ after normalization by expression of the control genes [phosphoglycerate kinase1 (PGK1), ribosomal protein L13 (RPL13) and hypoxanthine-guanine-phosphoribosyltransferase (HPRT)] and expressed in arbitrary units (a.u.).
The CYP1A1 ethoxyresorufin-O-deethylase activity (EROD) was determined in intact cells as described by Kennedy and Jones  with 5 μM ethoxyresorufin in growth medium as substrate in the presence of 1.5 mM salicylamide, to inhibit conjugating enzymes. The assay was performed at 37°C. The fluorescence of resorufin generated by the conversion of ethoxyresorufin by CYP1A1 was measured first, immediately after addition of reagents and then every 10 min for 60 min at 37°C in a Tecan infinite 200 fluorescence plate reader with excitation of 530 nm and emission at 595 nm. A standard curve was constructed using resorufin.
RNA interference assay
Cells were transfected with Invitrogen Stealth™ siRNA against CYP1A1 (1:1:1 mixture of #102535, #102537 and #175787) or scramble negative control (1:1:1 mixture of #12935-200, #12935-300 and #12935-400) with a final concentration of 30 nM. The transfection was carried out according to the Invitrogen forward transfection protocol for Lipofectamine™ RNAiMAX transfection reagent. After 48 h of transfection, the transfection medium was aspirated and replaced with exposure medium.
The statistical analyses were carried out using GraphPad Prism version 5.00 software (GraphPad Software Inc., San Diego, CA). Results are expressed as mean values ± standard deviations (SD) for the indicated number of independent measurements. Differences between the mean values recorded for different experimental conditions were evaluated by Student's t-test, and P values are indicated where appropriate in the figures and in their legends. A P value < 0.05 was considered as significant.
Intracellular and extracellular levels of gefitinib in sensitive and resistant NSCLC cell lines
In the first part of the study we evaluated the accumulation kinetics of 0.1 μM radiolabeled gefitinib in H322-sensitive and H1299-resistant cell lines during 24 h of treatment. Figure 1A shows a progressive decrease of the level of intracellular radiolabeled gefitinib only in the sensitive cell line. The decrease was detectable starting from 6 h of treatment, reaching a minimum level after 16 h. Similar results were obtained with a higher (1 μM) gefitinib concentration (not shown).
We then analyzed the effect of the intracellular gefitinib level on EGFR autophosphorylation in H322 cells. As reported in Figure 1B after 0.5 h, gefitinib inhibited EGFR autophosphorylation by around 50% and 80% at doses of 0.1 μM and 1 μM respectively; after 24 h these inhibitions were significantly reduced indicating a correlation between the intracellular gefitinib level and the inhibition of EGFR phosphorylation, confirming our previous results .
In an attempt to investigate whether the fall in intracellular gefitinib could be related to a lower influx, an enhanced efflux or metabolism of the drug, we firstly measured 5 min of [3H]gefitinib uptake in H322 cells treated with gefitinib for 0.5 h and 24 h (Figure 1C) and the level of intracellular gefitinib in the presence of inhibitors of specific efflux transporters (Figure 1D). As shown in Figure 1C, the initial rate of [3H]gefitinib uptake at 0.5 h and at 24 h was similar, suggesting that in the presence of an extracellular fixed concentration of drug, its influx is constant over time. Since it has been reported that gefitinib interacts with ABCG2 and to a lesser extent with ABCB1 , the intracellular levels of the radiolabeled drug were determined after dosing cells with the respective inhibitors Fumitremorgin C (Sigma Aldrich) and PSC833 (kindly provided by Novartis). We demonstrated only a slight increase in gefitinib content at 24 h in the presence of Fumitremorgin C (inhibition of ABCG2), whereas the inhibition of ABCB1 pump was ineffective (Figure 1D).
We then analyzed the distribution of radioactivity among intracellular, extracellular and macromolecule-linked compartments in another sensitive, EGFR wild-type cell line (Calu-3) and in resistant H1299 after 0.5 h and 24 h of treatment with radiolabeled gefitinib. As shown in Figure 2A, Calu-3 showed a significant drop in intracellular radioactivity, with a parallel increase in extracellular radioactivity after 24 h of incubation; by contrast, the radioactivity distribution was unchanged between 0.5 h and 24 h in H1299 cells. The amount of radioactivity in the NaOH fraction (macromolecule-linked) was less than 10% in both cell lines.
Since the measured radioactivity may be associated, at least in part, with gefitinib metabolites, the actual amount of gefitinib was monitored intracellularly and in the medium by LC-MS/MS after 0.5 h and 24 h of treatment in a panel of NSCLC cell lines showing either sensitivity (H322, H292, Calu-3) or resistance (H460, H1299, A549, Calu-1, SKLU-1) to the drug.
As shown in Figure 2B, the intracellular level of gefitinib was markedly reduced at 24 h (more than 80%) in all the sensitive cell lines, whereas the resistant ones showed a slight reduction (lower than 20%). Figure 2C shows that in sensitive cell lines, the extracellular level of gefitinib after 24 h of treatment was markedly reduced indicating that the increased radioactivity in the medium at 24 h (Figure 2A) was not due to gefitinib itself but to radiolabeled molecules probably derived from intracellular metabolism of gefitinib and then extruded into the extracellular compartment.
Taken together these results clearly demonstrate that the observed decrease in gefitinib content evident only in sensitive cells was due to a high rates of gefitinib metabolism.
Production of gefitinib metabolites by NSCLC cell lines and their effect on cell growth and EGFR autophosphorylation
Employing the standards kindly provided by AstraZeneca, we analyzed the appearance of the three main gefitinib metabolites (M1; M2; M3) inside and outside the cells after 0.5, 6 and 24 h of treatment with 0.1 μM gefitinib.
LC-MS/MS analysis (Figure 3A) showed that the M1 metabolite was present at a very low level in the intracellular compartment, mainly in sensitive cell lines, whereas M2 and M3 were undetectable.
The M1 metabolite was also present in the extracellular compartment (Figure 3B) at concentrations between 0.01 and 0.05 μM only in sensitive cell lines.
We then tested on sensitive and resistant cell lines whether metabolites M1, M2 and M3, when present in the growth medium at concentrations equivalent to gefitinib, were able to exert similar biological effects than gefitinib. As shown in Figure 3C, gefitinib and its metabolites inhibited, in a dose-dependent manner, cell proliferation in sensitive H322 cells with IC50 values of 0.13, 0.7, 0.5 and 1.4 μM for gefitinib, M1, M2 and M3 respectively. Figure 3D shows that gefitinib and metabolites inhibited with the same potency EGFR autophosphorylation. These results were further confirmed in both Calu-3 and H292 cell lines.
It should be noted that metabolites were only effective in all the resistant cells at very high concentrations (IC50 > 20 μM) (see Figure 3E for H1299) indicating that the metabolites themselves did not have an additive toxic effect (IC50 for gefitinib 9 μM).
Effect of gefitinib on CYP mRNAs expression and EROD activity in NSCLC cell lines
The baseline transcript levels of CYP1A1, CYP1A2, CYP2D6, CYP3A4 and CYP3A5 were determined in both sensitive and resistant cell lines by RT-PCR and data are summarized in Figure 4A. CYP1A1 and CYP1A2 were expressed at significant levels only in H322, H292 and Calu-3 cell lines, CYP2D6 was detected in all cell lines, whereas CYP3A4 was undetected. CYP3A5 was present at high level only in A549 cells.
The inducibility of individual CYP genes by gefitinib was then investigated and the levels of CYP1A1, CYP1A2, CYP2D6 and CYP3A5 mRNAs were assessed after treating cells with the drug. After 6 h, significantly higher gene expression levels of CYP1A1 and CYP1A2 were observed in all sensitive cell lines. By contrast no significant modulation of gene expression was observed in resistant cell lines (Figure 4B).
In order to evaluate whether modulation of the CYP1A1 transcript levels was associated with changes in the respective enzyme activity levels, we measured the activity of 7-ethoxyresorufin-O-deethylase (EROD), a commonly-used indicator of CYP1A activity , both basally and after exposure of cells to gefitinib.
In untreated cells, EROD activity was detectable only in sensitive cells, and gefitinib caused a significant increase in this activity (3-6 fold induction) with a maximum at 16-24 h (Figure 5A). Although both CYP1A1 and CYP1A2 carry out EROD activity, the 1A1 form has a much higher specific EROD activity than 1A2 . A further demonstration of CYP1A1 involvement came from the use of 10 μM α-NAP, a CYP1A1 inhibitor [28, 29] or from CYP1A1 silencing using siRNAs that significantly inhibited both baseline and gefitinib-induced EROD activity (Figure 5B).
We then tested the effect of other EGFR inhibitors (erlotinib, cetuximab, lapatinib) and of inhibitors of MAPK and PI3K/AKT/mTOR signalling transduction pathways on EROD activity in H322 cell line. As shown in Figure 5C erlotinib, cetuximab and lapatinib induced a significant increase in EROD activity comparable to that induced by gefitinib.
Both MEK inhibitors (PD98059 and U0126) strongly activated CYP1A1 activity, in contrast no increase in the activity was detectable after incubation with the inhibitors of PI3K/AKT/mTOR pathway tested (wortmannin, PI3K inhibitor; RAD001 mTOR inhibitor; NVP-BEZ235 PI3K and mTOR inhibitor)
Effect of hypoxia, cigarette smoke extract and cell density on gefitinib metabolism
Since it is known that hypoxia downregulates the expression and activity of many CYPs including CYP1A1 , we evaluated whether hypoxia could prevent gefitinib metabolism and its intracellular loss. The simultaneous exposure of H322 cells to gefitinib and hypoxia (Figure 6A) almost completely prevented gefitinib catabolism inside the cells. Differently, CYP1A1 activity was strongly induced in Calu-3 cells exposed to 2.5% cigarette smoke extract (CSE) for 24 h (see inset Figure 6B) and consequently gefitinib consumption (Figure 6B) was significantly expedited.
Moreover, as expected, cell density strongly affected the reduction in the intracellular level of gefitinib at 24 h in the Calu-3 line (Figure 6C) and consequently cells seeded at high and low density but with a similar growth-rate quotient, exhibited a significant difference in the sensitivity to gefitinib. Indeed, as shown in Figure 6D, cells at low density showed a 15-fold higher sensitivity to gefitinib (IC50 0.4 μM) as compared to cells at high density (IC50 6 μM).
Effects of CYP1A1 inhibition on the intracellular level of gefitinib, EGFR autophosphorylation and inhibition of cell growth
In an attempt to better characterize the role of CYP1A1 in sensitive cells, we measured the intracellular content of radiolabeled gefitinib in Calu-3 cells in the presence of 10 μM α-NAP. This inhibitor almost completely abolished the fall in intracellular gefitinib levels after 24 h of treatment (Figure 7A) and the intracellular appearance of the M1 metabolite (not shown).
To further demonstrate that α-NAP was able to maintain a high level of effective drug, Calu-3 cells were treated for 24 h with gefitinib in the presence or absence of α-NAP and then the medium was collected (conditioned media) and extracts from H322 cells exposed to conditioned media for 2 h were prepared to examine the inhibition of EGFR autophosphorylation by Western blot analysis. As shown in Figure 7B in H322 cells EGFR autophosphorylation was unaffected when cells were treated with gefitinib-conditioned medium collected from Calu-3 in the absence of α-NAP, in contrast when the inhibitor was present in the gefitinib-conditioned medium, EGFR autophosphorylation was completely inhibited. These results strongly suggest that in sensitive cells the metabolites released into the medium (low amount of M1 and other undetermined compounds) were ineffective in EGFR inhibition.
The high and constant drug level inside the cells obtained in the presence of α-NAP maintained a significant inhibition of EGFR p44/42 MAPK and AKT phosphorylation even after a prolonged period (48 h) of treatment (Figure 7C) when compared with cells incubated with gefitinib alone.
Sensitive cell lines were then treated with gefitinib in the presence of 10 μM α-NAP for 72 h in order to evaluate the effects of CYP1A1 inhibition on efficacy of gefitinib in inhibiting cell proliferation. In the presence of the inhibitor the IC50 for gefitinib, evaluated by crystal violet staining (Figure 7D-F) and confirmed by cell counting and MTT assay (not shown), was reduced 15, 3 and 6 times in Calu-3, H322 and H292 cells respectively.
Overall, these results show that inhibition of CYP1A1 is associated with reduced gefitinib metabolism, increased intracellular gefitinib content and increased drug efficacy in cultured NSCLC cells.
The cytochrome P450 system consists of a large number of enzyme subfamilies involved in the oxidative metabolism of xenobiotics including drugs. They are expressed mainly in the liver, but extra-hepatic expression of a number of these enzymes does occur . Although the primary site of gefitinib metabolism is the liver, tumor cell metabolism can significantly affect treatment effectiveness. However, to our knowledge, no studies have been performed addressing gefitinib metabolism in lung tumor cells.
The present study shows that the drop in gefitinib content observed in EGFR wild-type gefitinib-sensitive cell lines after 24 h of treatment was mainly due to gefitinib metabolism by CYP1A1 activity and not related to a time-dependent modification of influx or efflux processes. Our results indicate that there is a significant difference between gefitinib-sensitive and -resistant cell lines with regard to drug metabolism. Surprisingly, only sensitive cells were able to metabolize gefitinib and as a consequence, after 24 h of treatment, gefitinib disappeared both inside and outside the cells. The majority of radiolabeled gefitinib metabolites were present in the extracellular compartment as not well defined metabolites since we could barely detect the M1 metabolite and M2 or M3 were undetectable. In any case the metabolites present in the medium were not effective in inhibiting EGFR autophosphorylation as demonstrated by the conditioned medium experiment.
It has been reported that both gefitinib and its desmethyl metabolite (M3) formed through CYP2D6, inhibited with a similar potency and selectivity subcellular EGFR tyrosine kinase activity . However, M3 was 15 times less active in a cell-based assay and consequently it was assumed that this metabolite was unlikely to contribute to the activity of gefitinib in vivo due to poor cell penetration.
On the contrary, when metabolites M1, M2 and M3 were tested in our responsive cell models at concentrations equivalent to that of gefitinib, they exhibited a significant inhibition of EGFR autophosphorylation and proliferation in intact cells, indicating their ability to enter cells and to interact with the catalytic domain of EGFR. Finally, in gefitinib resistant cell lines M1, M2 and M3 metabolites were poorly effective (IC50 > 20 μM in proliferation assay) indicating that at least these metabolites did not produce additive toxic effects in NSCLC cell lines.
In contrast to its abundant hepatic expression, CYP3A4 seems to play a minor role in lung metabolism, being expressed in only about 20% of cases . Real-time PCR analysis confirmed the lack of expression of this isoform in our NSCLC cell models, as reported for A549 cells . CYP2D6 was detected in all cell lines, whereas both CYP1A1 and CYP1A2 were expressed at significant levels in sensitive cells. Inducibility of CYP1A1 and CYP1A2 transcripts by gefitinib was clearly demonstrated in sensitive cell lines, while induction of CYP1A1 mRNA was not detected in resistant cell lines. EROD activity demonstrated a 3-6 fold induction of CYP1A1 elicited by gefitinib in sensitive cells. To the best of our knowledge, this is the first time that the induction by gefitinib of relevant metabolic enzyme(s) has been demonstrated.
The reason why gefitinib induces CYP expression and activity only in sensitive cells could be ascribed to the ability of gefitinib to inhibit signal transduction pathway downstream EGFR. It has been recently demonstrated that EGF represses the dioxin-mediated induction of CYP1A1 in normal human keratinocytes preventing recruitment of the p300 coactivator . Therefore, EGFR signalling is a repressor of the aryl hydrocarbon receptor and regulates the transcription of numerous genes including CYP1A1. In this context, EGFR inhibitors such as gefitinib, erlotinib, lapatinib or cetuximab might affect the induction of CYP1A1 in those cell types in which the drug effectively inhibits signalling controlled by EGFR. The inhibition of MAPK pathway might represent a link between EGFR inhibition and CYP1A1 induction since PD98059 and U0126, well known MEK1/2 inhibitors, induced CYP1A1 activity as did gefitinib in H322 cells, while none of PI3K/AKT/mTOR inhibitors tested was effective. It is noteworthy that constitutive activation of signaling pathways downstream of EGFR is a recognized mechanism or resistance against reversible EGFR tyrosine kinase inhibitors .
We surmise that gefitinib metabolism is a consequence and not the cause of drug responsiveness and might be useful for early evaluation of response to gefitinib in tumor lacking activating mutations.
Since CYP1A1 inducibility strongly correlates with CYP1A1 gene polymorphism  we also tested the genotypic asset of our cell lines regarding the two main polymorphic forms of CYP1A1 (CYP1A1*2A and CYP1A1*2C). All the tested cell lines carried a wild type homozygous genotype for both the polymorphisms and so we can exclude that different genotypes are involved in the different capability of metabolizing gefitinib.
The role of CYP1A1 polymorphism as a predictor of clinical outcome to EGFR-TKIs in patients with advanced lung cancer has very recently been reported . The authors note that CYP1A1*2A polymorphism correlates with the response to EGFR-TKIs of NSCLC, wild type T/T patients having an improved response of inhibitors versus T/C and C/C alleles.
Studies have shown that the hepatic metabolism of gefitinib is primarily catalyzed via CYP3A4, consequently the effects of known inducers (phenytoin, carbamezepine, rifampicin) and inhibitors (ketoconazole, itraconazole, erythromycin and claritromycin) of CYP3A4 activity have been investigated .
Our results indicate that, in NSCLC cells metabolizing gefitinib, CYP1A1 inhibition could lead to increased local exposure to the active drug. In fact, inhibition by α-naphthoflavone was associated with lower gefitinib metabolism and consequently with a prolonged exposure to locally active drug. This leads to enhanced inhibition of EGFR, MAPK and AKT phosphorylation and cell proliferation, with the result of reduced IC50 for gefitinib in proliferation assays of EGFR wild-type NSCLC cell lines.
From a medicinal chemistry perspective, these results stress the importance of considering drug pharmacokinetics at the intratumoral cellular level, focusing on the roles of transport and metabolism in the target cells. While the structure of gefitinib makes it a substrate of transporters , thus enhancing its activity toward intracellular targets, it also harbors metabolic liabilities in tumor cells. From this point of view, its interaction with CYP3A4 seems mainly related to total-body exposure gefitinib, while CYP1A1 is mainly responsible of its metabolism in tumor cells. A program of structural optimization should thus consider the effects of structure modulation on all these processes in combination.
In addition, a strategy of increasing gefitinib activity by using specific CYP inhibitors, could be pursued in the context of optimizing the use of gefitinib for the treatment of EGFR wild-type gefitinib-sensitive tumors.
Interstitial lung disease (ILD) has been reported as a serious adverse effect of gefitinib treatment . The incidence of acute ILD during gefitinib treatment varies between different ethnic groups occurring more frequently in Japanese patients (4%-6%) than in Caucasian (0.2-0.3%) . Although the precise mechanism of ILD induced by gefitinib remains unknown, it has been proposed that bioactivation of gefitinib by CYP1A1 in the lung may be related to the risk of developing ILD mainly in smokers . In this context the optimisation of CYP1A1 inhibition may not only improve gefitinib efficacy but even reduce the incidence of ILD.
cigarette smoke extract
epidermal growth factor receptor
mitogen-activated protein kinase
non small cell lung cancer
tyrosine kinase inhibitor.
Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011, 364: 947-955.
Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010, 28: 744-752.
Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006, 24: 5034-5042.
Janne PA, Gray N, Settleman J: Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 2009, 8: 709-723.
Engelman JA, Janne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008, 14: 2895-2899.
van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009, 35: 692-706.
Huang Y, Sadee W: Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2006, 239: 168-182.
Li X, Kamenecka TM, Cameron MD: Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 2009, 22: 1736-1742.
Galetti M, Alfieri RR, Cavazzoni A, La Monica S, Bonelli M, Fumarola C, Mozzoni P, De Palma G, Andreoli R, Mutti A: Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Biochem Pharmacol. 2010, 80: 179-187.
Swaisland HC, Cantarini MV, Fuhr R, Holt A: Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet. 2006, 45: 633-644.
McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ, Hutchison M: Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica. 2005, 35: 39-50.
Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007, 13: 3731-3737.
McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CM, Clarkson-Jones JA, Herron W, Swaisland HC: Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica. 2004, 34: 917-934.
McKillop D, McCormick AD, Miles GS, Phillips PJ, Pickup KJ, Bushby N, Hutchison M: In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica. 2004, 34: 983-1000.
Androutsopoulos VP, Tsatsakis AM, Spandidos DA: Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009, 9: 187-
Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I: Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics. 2007, 17: 731-742.
Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, Borlak J: Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect. 2006, 114: 1655-1661.
La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A: Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol. 2009, 78: 460-468.
Carp H, Janoff A: Possible mechanisms of emphysema in smokers. In vitro suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. Am Rev Respir Dis. 1978, 118: 617-621.
Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I: Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region. Clin Investig. 1994, 72: 240-248.
Hayashi SI, Watanabe J, Nakachi K, Kawajiri K: PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res. 1991, 19: 4797-
Cavazzoni A, Alfieri RR, Carmi C, Zuliani V, Galetti M, Fumarola C, Frazzi R, Bonelli M, Bordi F, Lodola A: Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther. 2008, 7: 361-370.
Alfieri RR, Bonelli MA, Cavazzoni A, Brigotti M, Fumarola C, Sestili P, Mozzoni P, De Palma G, Mutti A, Carnicelli D: Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress. J Physiol. 2006, 576: 391-401.
Kennedy SW, Jones SP: Simultaneous measurement of cytochrome P4501A catalytic activity and total protein concentration with a fluorescence plate reader. Anal Biochem. 1994, 222: 217-223.
Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004, 65: 1485-1495.
Shimada T, Gillam EM, Sutter TR, Strickland PT, Guengerich FP, Yamazaki H: Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997, 25: 617-622.
Doostdar H, Burke MD, Mayer RT: Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology. 2000, 144: 31-38.
Shimada T, Yamazaki H, Foroozesh M, Hopkins NE, Alworth WL, Guengerich FP: Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol. 1998, 11: 1048-1056.
Dubey RK, Gillespie DG, Zacharia LC, Barchiesi F, Imthurn B, Jackson EK: CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension. 2003, 41: 807-813.
Fradette C, Du Souich P: Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab. 2004, 5: 257-271.
van Schaik RH: CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008, 11: 77-98.
McKillop D, Guy SP, Spence MP, Kendrew J, Kemp JV, Bushby N, Wood PG, Barnett S, Hutchison M: Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica. 2006, 36: 29-39.
Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, Raunio H: Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol. 1997, 16: 242-249.
Hukkanen J, Lassila A, Paivarinta K, Valanne S, Sarpo S, Hakkola J, Pelkonen O, Raunio H: Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 2000, 22: 360-366.
Sutter CH, Yin H, Li Y, Mammen JS, Bodreddigari S, Stevens G, Cole JA, Sutter TR: EGF receptor signaling blocks aryl hydrocarbon receptor-mediated transcription and cell differentiation in human epidermal keratinocytes. Proc Natl Acad Sci USA. 2009, 106: 4266-4271.
Zhou SF, Liu JP, Chowbay B: Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009, 41: 89-295.
Nie Q, Yang XN, An SJ, Zhang XC, Yang JJ, Zhong WZ, Liao RQ, Chen ZH, Su J, Xie Z, Wu YL: CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Eur J Cancer. 2011, 47: 1962-1970.
Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T: Severe acute interstitial pneumonia and gefitinib. Lancet. 2003, 361: 137-139.
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M: Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008, 177: 1348-1357.
This work was supported by: Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan grant IG 8856; AstraZeneca SpA Basiglio (MI); Associazione Augusto per la vita (Novellara, RE); Associazione Davide Rodella, Montichiari, BS; Ministero della Salute (Programma straordinario di ricerca oncologica 2006) Regione Emilia Romagna; Associazione Marta Nurizzo, Brugherio MI; Associazione Chiara Tassoni, Parma; A.VO.PRO.RI.T., Parma.
The authors declare that they have no competing interests.
MG carried out radiolabeled gefitinib experiments, interpreted the results and assisted with the draft of the manuscript; ST carried out EROD experiments; RA carried out LC-MS/MS analysis; PM and GDP carried out RT-PCR experiments; AC and MB carried out Western blot analysis; CF, SLM and EG carried out cell growth experiments; AM, MT, EM and AA critically revised the manuscript; MM performed the statistical analysis; PGP designed the project and assisted with the draft of the manuscript; RRA, analyzed the results and wrote the manuscript. All authors read and approved the final manuscript.
Roberta R Alfieri, Maricla Galetti contributed equally to this work.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Alfieri, R.R., Galetti, M., Tramonti, S. et al. Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Mol Cancer 10, 143 (2011). https://doi.org/10.1186/1476-4598-10-143
- Lung cancer